Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2018 Jan;89 (2018)(1):1-9.
doi: 10.5414/CN109245.

Long-term Treatment With Biosimilar Epoetin-α (HX575) in Hemodialysis Patients With Renal Anemia: Real-World Effectiveness and Safety in the MONITOR-CKD5 Study

Free PMC article
Observational Study

Long-term Treatment With Biosimilar Epoetin-α (HX575) in Hemodialysis Patients With Renal Anemia: Real-World Effectiveness and Safety in the MONITOR-CKD5 Study

Gérard London et al. Clin Nephrol. .
Free PMC article


Aims: To assess real-world effectiveness and safety of intravenous (IV) HX575, a biosimilar epoetin-α, in hemodialysis (HD) patients.

Materials and methods: This prospective, observational, pharmacoepidemiological study of adult HD patients treated with IV HX575 for renal anemia for up to 24 months was conducted in 114 centers in 10 European countries. Of 2,086 enrolled subjects (safety sample), 2,023 had ≥ 1 follow-up visit (effectiveness sample).

Results: Most (59.3%) patients were male, median age was 68 years. At enrollment, most (82.5%) had been treated with an erythropoiesis-stimulating agent, and 73.0% had adequate iron stores. At baseline, mean (± standard deviation) baseline hemoglobin (Hb) was 11.09 (± 1.14) g/dL and HX575 dose 106.5 (± 78.7) international units (IU)/kg/week; at month 24, Hb was 11.25 (± 1.19) g/dL and HX575 dose 113.0 (± 102.5) IU/kg/week. Variations in mean HX575 dose and Hb over the study were not statistically significant. As to safety, 140 patients (6.7%) experienced ≥ 1 adverse event; of these, 19 events (16 patients; 0.8%) were related to HX575 treatment, 148 (108 patients; 5.2%) were reported as serious, including 12 events in 11 patients (0.5%) stated to be related. No cases of anti-epoetin antibodies or pure red cell aplasia were reported.

Conclusions: MONITOR-CKD5 confirmed the real-world effectiveness and safety profile of IV biosimilar HX575. HD patients treated for up to 24 months showed stable dosing patterns and Hb outcomes. The safety profile of HX575 is likewise comparable to reference epoetin-α. .


Figure 1.
Figure 1.. Patient disposition. *Total number of deaths = 288; death as reason for premature study stop = 282; death occurred at study end in 6 patients. ESA = erythropoiesis-stimulating agent.
Figure 2.
Figure 2.. Binocrit® dose and Hb evolution. IU/kg/wk = international units per kilogram per week; SD = standard deviation; Hb = hemoglobin; g/dL = grams per deciliter.

Similar articles

See all similar articles

Cited by 3 articles


    1. Eckardt KU Pathophysiology of renal anemia. Clin Nephrol. 2000; 53: S2–S8. - PubMed
    1. Stengel B Billon S Van Dijk PC Jager KJ Dekker FW Simpson K Briggs JD Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Nephrol Dial Transplant. 2003; 18: 1824–1833. - PubMed
    1. Locatelli F Bárány P Covic A De Francisco A Del Vecchio L Goldsmith D Hörl W London G Vanholder R Van Biesen W Abramovicz D Cannata-Andia J Cochat P Eckardt KU Fouque D Heimburger O Jäger K Jenkins S Lindley E MacLeod A Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant. 2013; 28: 1346–1359. - PubMed
    1. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012; 2: 279–335.
    1. European Medicines Agency. European Public Assessment Report for Binocrit. Available at (Last accessed December 30, 2016).

Publication types